David L Laitinen1, Shivaji Manthena. 1. Global Health Economics & Outcomes Research, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064-6145, USA. dave.laitinen@abbott.com
Abstract
INTRODUCTION: Low concentration of high-density lipoprotein cholesterol (HDL-C) has increasingly been recognized as a strong and independent predictor of cardiovascular risk. The aim of this study was to determine the association between change in HDL-C concentration from baseline and risk of a major cardiovascular event in a commercially insured population cohort with suboptimal HDL-C and low-density lipoprotein cholesterol (LDL-C) concentrations at baseline. METHODS: A retrospective longitudinal survival analysis was conducted using claims data from a large, commercial US health plan. To be included, patients had to be > or =50 years of age on the index date (laboratory test date between January 1, 2000 and December 31, 2003 on which both their LDL-C and HDL-C were not at goal), be continuously enrolled for a minimum of 6 months prior to and 12 months after the index date, and had to have at least one other laboratory panel result within 1 year prior to the cardiovascular event or study disenrollment. Cox proportional hazards analysis was conducted to assess the association between change in HDL-C concentrations and risk of a major cardiovascular event (defined as a > or =1-day hospitalization for a cardiovascular disease [CVD] diagnosis or an invasive cardiovascular procedure) within 5 years of the index date, after adjusting for covariates. RESULTS: A 0.026 mmol/L (1 mg/dL) increase in HDL-C from baseline was associated with a statistically significant 1.9% decreased risk of a major cardiovascular event (P<0.0001; hazard ratio: 0.981; 95% CI: 0.974, 0.989), after adjustment for covariates. CONCLUSION: Our finding of an inverse association between change in HDL-C concentrations and risk of a major cardiovascular event confirms previously reported results. Increasing HDL-C concentrations may serve as an effective measure for preventing future cardiovascular events.
INTRODUCTION: Low concentration of high-density lipoprotein cholesterol (HDL-C) has increasingly been recognized as a strong and independent predictor of cardiovascular risk. The aim of this study was to determine the association between change in HDL-C concentration from baseline and risk of a major cardiovascular event in a commercially insured population cohort with suboptimal HDL-C and low-density lipoprotein cholesterol (LDL-C) concentrations at baseline. METHODS: A retrospective longitudinal survival analysis was conducted using claims data from a large, commercial US health plan. To be included, patients had to be > or =50 years of age on the index date (laboratory test date between January 1, 2000 and December 31, 2003 on which both their LDL-C and HDL-C were not at goal), be continuously enrolled for a minimum of 6 months prior to and 12 months after the index date, and had to have at least one other laboratory panel result within 1 year prior to the cardiovascular event or study disenrollment. Cox proportional hazards analysis was conducted to assess the association between change in HDL-C concentrations and risk of a major cardiovascular event (defined as a > or =1-day hospitalization for a cardiovascular disease [CVD] diagnosis or an invasive cardiovascular procedure) within 5 years of the index date, after adjusting for covariates. RESULTS: A 0.026 mmol/L (1 mg/dL) increase in HDL-C from baseline was associated with a statistically significant 1.9% decreased risk of a major cardiovascular event (P<0.0001; hazard ratio: 0.981; 95% CI: 0.974, 0.989), after adjustment for covariates. CONCLUSION: Our finding of an inverse association between change in HDL-C concentrations and risk of a major cardiovascular event confirms previously reported results. Increasing HDL-C concentrations may serve as an effective measure for preventing future cardiovascular events.
Authors: Martin Bahls; Matthias W Lorenz; Marcus Dörr; Lu Gao; Kazuo Kitagawa; Tomi-Pekka Tuomainen; Stefan Agewall; Gerald Berenson; Alberico L Catapano; Giuseppe D Norata; Michiel L Bots; Wiek van Gilst; Folkert W Asselbergs; Frank P Brouwers; Heiko Uthoff; Dirk Sander; Holger Poppert; Michael Hecht Olsen; Jean Philippe Empana; Ulf Schminke; Damiano Baldassarre; Fabrizio Veglia; Oscar H Franco; Maryam Kavousi; Eric de Groot; Ellisiv B Mathiesen; Liliana Grigore; Joseph F Polak; Tatjana Rundek; Coen DA Stehouwer; Michael R Skilton; Apostolos I Hatzitolios; Christos Savopoulos; George Ntaios; Matthieu Plichart; Stela McLachlan; Lars Lind; Peter Willeit; Helmuth Steinmetz; Moise Desvarieux; M Arfan Ikram; Stein Harald Johnsen; Caroline Schmidt; Johann Willeit; Pierre Ducimetiere; Jackie F Price; Göran Bergström; Jussi Kauhanen; Stefan Kiechl; Matthias Sitzer; Horst Bickel; Ralph L Sacco; Albert Hofman; Henry Völzke; Simon G Thompson Journal: Eur J Prev Cardiol Date: 2019-10-16 Impact factor: 7.804
Authors: Sebastian Schneeweiss; Jeremy A Rassen; Robert J Glynn; Jessica Myers; Gregory W Daniel; Joseph Singer; Daniel H Solomon; Seoyoung Kim; Kenneth J Rothman; Jun Liu; Jerry Avorn Journal: BMC Med Res Methodol Date: 2012-11-26 Impact factor: 4.615